

IN THE SPECIFICATION

Please replace the paragraph on page 26, lines 19-24 with the following new paragraph:

“Additionally, as demonstrated by the BIAcore results shown in Example 43, the antibodies of the present invention exhibit a binding affinity to the erythropoietin receptor within one hundred fold of the binding affinity of endogenous human erythropoietin to the erythropoietin receptor. A high (~1 nM) and low (~1  $\mu$ M) affinity of the EPO receptor for EPO has been reported resulting from two nonequivalent receptor binding sites on EPO (See Philo, J. S. et al., *Biochemistry*, 35:1681 (1996)).”